Literature DB >> 8636303

Expression of exon 3-retaining and -deleted human growth hormone receptor messenger ribonucleic acid isoforms during development.

G Zogopoulos1, R Figueiredo, A Jenab, Z Ali, Y Lefèbvre, C G Goodyer.   

Abstract

Recent investigations have suggested that human GH (hGH) and its receptor may have specific functions during human fetal life. To improve our understanding of the mechanisms of hGH action during gestation, we characterized the ontogenic appearance of hGH receptor messenger ribonucleic acid (mRNA) in multiple human fetal and postnatal tissues. Using RT-PCR assays, followed by Southern hybridization to confirm the specificity of the amplified fragments, we scanned the entire coding region of the hGH receptor mRNA. Transcription of the hGH receptor gene was observed in all fetal tissues studied (liver, kidney, skin, muscle, lung, adrenal, spleen, intestine, central nervous system, pancreas, and placental villi) from the earliest stage that could be examined [7-14.8 weeks fetal age (FA)]. Furthermore, we identified only 2 isoforms of the hGH receptor mRNA-coding region: exon 3 can be retained or deleted. Surprisingly, we found individual-specific, not tissue-specific, expression patterns of these two transcripts when we examined multiple tissues (n = 2-6) from 15 individuals (11.5-33 weeks FA); this individual-specific pattern of expression is maintained in cultured dermal fibroblasts for at least 12 generations (n = 2; 16 and 20 weeks FA). In addition, a cross-sectional study of 78 individuals (9 weeks FA to 43 yr postnatal age) showed that the exon 3-deleted transcript is predominantly expressed in tissues from fetuses of 9-20 weeks FA (P < 0.002). Finally, we showed that the absence of exon 3 from the mRNA is not due to genomic deletion of exon 3 by amplifying exon 3 from genomic DNA of 3 fetuses (13.3-19 weeks FA) expressing only the exon 3-deleted mRNA transcript. We conclude that 1) transcription of the hGH receptor gene occurs in multiple tissues as early as the first trimester of human fetal life; 2) the exon 3-retaining and -deleted transcripts are the only two isoforms of the hGH receptor mRNA-coding region during gestation; and 3) the pattern of expression of these transcripts is individual specific and may be developmentally regulated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636303     DOI: 10.1210/jcem.81.2.8636303

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Transcription from the P2 promoter of the growth hormone receptor gene involves members of the Sp transcription factor family.

Authors:  T E Adams
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

Review 2.  Growth hormone during development.

Authors:  Joy Osafo; Yuhong Wei; Gurvinder Kenth; Cynthia Gates Goodyer
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

3.  Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism.

Authors:  M L Stallings-Mann; R L Ludwiczak; K W Klinger; F Rottman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

Review 4.  Neural growth hormone: an update.

Authors:  Steve Harvey; Kerry Hull
Journal:  J Mol Neurosci       Date:  2003-02       Impact factor: 3.444

Review 5.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  CT pulmonary densitovolumetry in patients with acromegaly: a comparison between active disease and controlled disease.

Authors:  Gustavo B Camilo; Alysson R S Carvalho; Dequitier C Machado; Roberto Mogami; Pedro L Melo; Agnaldo J Lopes
Journal:  Br J Radiol       Date:  2015-08-06       Impact factor: 3.039

7.  Correlations between forced oscillation technique parameters and pulmonary densitovolumetry values in patients with acromegaly.

Authors:  G B Camilo; A R S Carvalho; D C Machado; R Mogami; L Kasuki; M R Gadelha; P L Melo; A J Lopes
Journal:  Braz J Med Biol Res       Date:  2015-08-04       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.